MedTrace Logo

Investigation of the Pharmacokinetic Profile of CBD

NCT05269706 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-14

No results posted yet for this study

Summary

The goal of the current study is to evaluate the bioavailability of CBD in normal healthy Individuals. This is an open cross-overdesign study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.

Conditions

Interventions

DRUG

Cannabidiol 200mg

Cannabidiol 200mg (twice daily)

DRUG

Epidiolex

Epidiolex 400mg (twice daily)

DRUG

Cannabidiol 400mg

Cannabidiol 400mg (twice daily)

DRUG

Placebo

Matching Placebo (Twice Daily)

Sponsors & Collaborators

  • Yasmin Hurd

    lead OTHER

Principal Investigators

  • Yasmin Hurd, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2023-02-16
Completion
2023-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05269706 on ClinicalTrials.gov